Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
JCO Precision Oncology|October 26, 2019
Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical ProstatectomyPedro Isaacsson Velho, David Lim, Hao Wang, et al.
BMC Urology|December 12, 2023
The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocolJeziel Basso, Juliana Beust de Lima, Marina Bessel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2024
Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsPedro Isaacsson Velho, Diogo Assed Bastos, Pedro Tofani Saint'ana, et al.
European Urology Oncology|June 16, 2020
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerMatthew P Deek, Kekoa Taparra, Ryan Phillips, et al.
JCO Precision Oncology|May 29, 2020
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsEmmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
The Oncologist|November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate CancerLaura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
European Urology|January 18, 2025
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety AnalysisSilke Gillessen, Bertrand Tombal, Fabio Turco, et al.
European Urology|January 9, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedMatthew P Deek, Kim Van der Eecken, Ryan Phillips, et al.
European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.
Pageof 4